---
title: "US Rare Disease Biotechs Navigate Regulatory Scrutiny and Revised 2026 Guidance"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/295775479.md"
description: "US biopharmaceutical firms are facing heightened volatility in 2026 as post-market safety data and clinical milestones dictate market action. Neurocrine shares slipped amid drug safety scrutiny, while Sarepta narrowed its full-year revenue outlook following a leadership transition."
datetime: "2026-08-13T09:42:39.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/295775479.md)
  - [en](https://longbridge.com/en/news/295775479.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/295775479.md)
generator: "portal-rs"
---

# US Rare Disease Biotechs Navigate Regulatory Scrutiny and Revised 2026 Guidance

US biotechnology companies specializing in rare disease therapeutics are navigating a complex landscape in the second half of 2026, balancing late-stage clinical progress with intensifying regulatory oversight. Recent quarterly filings and FDA adverse event disclosures highlight how rapidly market valuations can shift when expectations around commercial rollouts and drug safety profiles are challenged.

### Neurocrine Biosciences (NBIC.US)

Shares of Neurocrine Biosciences fell **5.8%** following reports of patient fatalities and severe health complications potentially linked to its Prader-Willi syndrome drug, Vykat XR. According to the FDA's adverse event reporting system, seven deaths and over 100 severe incidents were logged by July 31, 2026. Chief Executive Officer Kyle Gano stated that the company "did not see a relationship between the deaths and Vykat XR." The drug was recently integrated into the company's portfolio through a **USD 2.9 billion** all-cash buyout of Soleno Therapeutics. According to the Q2 2026 earnings report, Vykat XR generated **USD 54 million** in net product sales since the acquisition's close in May. Despite the current scrutiny, the company anticipates robust financial growth, projecting its earnings per share to jump **25.23%** to USD 9.73 over the coming year.

### Sarepta Therapeutics (SRPT.US)

Gene therapy developer Sarepta Therapeutics reported Q2 2026 total revenues of **USD 401.3 million**, closing the quarter with approximately **USD 945 million** in cash and investments. Its traditional PMO therapies generated the bulk of its top line, accounting for **USD 230.6 million** in net product revenue, while the newly launched genetic treatment ELEVIDYS contributed **USD 98.1 million**. Concurrent with its earnings release, the company revised its full-year 2026 net product revenue guidance to a tighter range of **USD 1.2 billion to USD 1.3 billion**. The firm is also undergoing a major leadership transition, with Dr. Michael Severino officially stepping in as CEO in late July. On the regulatory front, the FDA has accepted supplemental New Drug Applications (sNDA) to convert the accelerated approvals of AMONDYS 45 and VYONDYS 53 into traditional approvals, setting a PDUFA target date of February 28, 2027.

The divergence in recent stock performances underscores the high-stakes nature of commercializing specialized orphan drugs, where investors are actively monitoring safety dashboards and label expansions to determine intraday capital allocations across the healthcare sector.

*This article does not constitute investment advice.*

### Related Stocks

- [SRPT.US](https://longbridge.com/en/quote/SRPT.US.md)

## Related News & Research

- [Wells Fargo Remains a Buy on Sarepta Therapeutics (SRPT)](https://longbridge.com/en/news/295099820.md)
- [Sarepta names former Abbvie president as CEO as Ingram retires](https://longbridge.com/en/news/293938995.md)
- [Your portfolio can recover from a bear market, but can it survive you living to 110?](https://longbridge.com/en/news/297058415.md)
- [Nvidia Q2 Preview: SpaceX Is Becoming the 'Fifth Horseman,' Gene Munster Says](https://longbridge.com/en/news/296931540.md)
- [New Concept Energy Shareholders Approve Equity Issuance Plan](https://longbridge.com/en/news/296823498.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**